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outcomes. Regarding the acceptability threshold in Poland cysteamine therapy 
can be considered a cost-effective technology compared with CaST in patients 
who began treatment before the age of two.
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Objectives: To assess the cost-effectiveness of sugammadex compared with 
neostigmine + glycopyrrolate as a reversal agent for moderate and deep rocu-
ronium or vecuronium-induced neuromuscular blockade (NMB) in the elective 
setting in England and Wales, when extubation occurs at a train-of-four (TOF) ratio 
of 0.9. MethOds: A decision tree comparing the cost-effectiveness of sugamma-
dex versus neostigmine + glycopyrrolate when reversing moderate or deep NMB 
induced by commonly used neuromuscular blocking agents (NMBAs) (atracurium/
rocuronium/vecuronium) was developed. Extubation was modelled to occur at a 
TOF ratio of 0.9, as may happen when using objective NMB monitoring to deter-
mine when to safely extubate. Time to recovery was used to calculate the cost 
of patients recovering in theatre based on both the average cost per minute of 
theatre time, and operating room (OR) staff costs per minute. Effectiveness was 
measured by the number of prolonged paralysis cases prevented by each treat-
ment regimen. Results: Reversal of moderate NMB: when considering average 
cost per minute of theatre time, results show that sugammadex strategies are 
dominant compared with all assessed comparators. When considering OR staff 
cost per minute, results show that rocuronium with sugammadex is dominant 
over all assessed comparators, with the exception of atracurium with neostigmine 
+ glycopyrrolate (ICER< £100). Reversal of deep NMB: when considering either 
costing scenario, results show that sugammadex strategies are dominant over 
all assessed comparators, with the exception of atracurium with neostigmine + 
glycopyrrolate (ICER < £330). cOnclusiOns: In clinical settings where extubation 
occurs at a TOF ratio of 0.9, and time savings may be realized for all OR staff, under 
both moderate and deep NMB scenarios in the elective surgery setting, sugam-
madex is either dominant or shows reasonable levels of cost-effectiveness (with 
low ICERs < £330 when not dominant against neostigmine+ glycopyrrolate), whilst 
also filling an unmet need for deep NMB reversal.
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Objectives: A vaccine is licensed in Europe for the prevention of Herpes Zoster 
(HZ) and postherpetic neuralgia (PHN) in adults aged ≥ 50 years. The objective of 
this study was to assess the cost-effectiveness of a vaccination programme in 
Germany in this population. MethOds: An existing European Markov Model was 
adapted to the German health care setting and cost-effectiveness outcomes were 
assessed from the statutory health insurance (SHI) and from the societal perspec-
tive. The Markov Model compares a HZ vaccination policy for adults aged ≥ 50 
years with a no vaccination policy. Health states considered are healthy, HZ, PHN, 
healthy post-HZ and death. HZ and PHN states are further split by pain severity 
(mild, moderate or severe). Model outcomes include cost/HZ case avoided, cost/
PHN case avoided and cost/quality-adjusted life year (QALY) gained. Additionally 
we assessed the number needed to vaccinate (NNV) to avoid one case of HZ or PHN. 
Input data were obtained from German data sources, international and German 
study results as well as published literature. Discounting was done in accordance 
to guidelines from the German Institute for Quality and Efficiency in Health Care 
(IQWiG). Results: Preliminary results of the base-case analysis show incremen-
tal cost-effectiveness and cost-utility ratios (ICER) in amount of € 2,223 per HZ 
case avoided and € 22,923 per QALY gained from a payer perspective. In sensitiv-
ity analyses discount rates, vaccine prices and no hospitalization assumption 
showed a major impact on the results. cOnclusiOns: Our cost-effectiveness 
analysis shows that a HZ vaccination policy for adults aged ≥ 50 years in Germany 
could provide public health and economic effects in the German health care 
system.
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Objectives: An increased risk for fractures has been observed in patients 
treated with opiates, possibly resulting from falls related to central nervous 
system effects, such as dizziness. Observational data suggest that the semisyn-
thetic opioid, buprenorphine, may be associated with a lower fracture risk than 
some other opiates such as tramadol. Our objective was to perform a preliminary 
analysis to explore whether a buprenorphine-class drug has the potential to be 
cost-effective due to a reduced risk for fracture. MethOds: Decision-analytic 
modeling was used to project fracture-related outcomes and costs over 1 year. 
Quality-adjusted life-years (QALYs) and costs (in 2012 pounds sterling) were esti-
mated from a health service perspective. Odds ratios for forearm, hip, and spine 
fractures, by drug, estimated from real-world hospital discharge data (Vestergaard 
et al., 2006), were applied to the risk for fracture in the general population. 
ing ponatinib provided more than double (2.2-fold) the MCyR months at 36% 
higher cost compared to the 2G TKI strategy. The average cost/MCyR month 
with ponatinib was lower than the average cost/MCyR month with 2G TKIs. 
While there are limitations with the methology and assumptions of the model, 
this analysis suggests treatment with ponatinib may provide good value for 
ponatinib-eligible Italian patients.
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Objectives: To estimate the cost-effectiveness of using the capsaicin patch 
QUTENZATM prior to use of more costly neuropathic pain medications for individu-
als with peripheral neuropathic pain (PnP). MethOds: A decision tree and Markov 
model was developed using inputs from a prospective, observational study. This 
study provided estimates of clinical efficacy, health utility and resource use. The 
model considered two treatment strategies: 1. a capsaicin patch followed by pre-
gabalin and then a subsequent last-line therapy, and 2. no exposure to a capsaicin 
patch. A systematic review and meta-analysis were used to estimate the effective-
ness of pregabalin. Response was defined as a ≥ 50% reduction in pain at week-8. 
Patients who responded were assumed to experience pain relief and increase in 
health-related quality of life until the resolution of pain (or death). Non-responders 
were assumed to switch therapy, and individual’s that failed last-line therapy were 
assumed to experience baseline pain (unless resolution of pain or death). Costs 
were based on published sources. The primary outcome was the incremental cost-
effectiveness ratio (ICER). The perspective was the UK National Health Service and 
personal social services. Results: Key parameter estimates derived from the 
observational study were: the probability of response for capsaicin patch (29.5%), 
the mean number of patches per application (1.5), the mean time to retreatment 
(218 days), The baseline EQ-5D score was 0.370; response was associated with an 
increase in EQ-5D utility of 0.353 from baseline. The base-case ICER was £2,292 per 
quality-adjusted life-year (QALY). This varied by time horizon. Probabilistic sensi-
tivity analysis suggested that over a lifetime horizon, a treatment strategy placing 
capsaicin patches before pregabalin had a 99.9% probability of being cost effective 
at a willingness-to-pay threshold of £20,000. cOnclusiOns: The capsaicin patch 
used before pregabalin was a highly cost-effective treatment in the management 
of peripheral neuropathic pain.
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Objectives: To evaluate the cost effectivenss of Thiopentone and Propofol for over 
night induction anesthesia in a tertiary care hospital. MethOds: A prospective 
observational study in which the patients scheduled for general anaesthesia were 
adminsitred EQ5D 5L(Qol question aire) after six hour and 24 hours of administering 
Induction Aneasthesia. Kuppuswamy scale was applied to asses the socioeconomic 
status along with the demographic detials Results: The average of EQ5D5L scores 
for Propofal was 14.2 and for Thiopentone 16.0. The cost of the Propofol brand used 
in hospital were 250INR and 260INR. Thiopentone , only one brand was avialable 
costing 62 INR. The Propofol was the most commonly used induction anesthetic 
and it costs more than 4 times of Thipentone. The patients socioeconomic catego-
rirzation based on Kuppuswmy Scale revealed nearly 50% of patients belonged to 
lower middle class and 35% middle class and rest of the patients to Upper class. 
Incremental cost effectivness ratio for Thiopentone agianst Propofol was found 
to be -110; cOnclusiOns: The Propofol although expensive does not offer any 
advantage over the Thiopentone as for quality of life among patients who under 
went induction anethesia
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Objectives: To perform a cost-effectiveness analysis (CEA) of cysteamine in the 
treatment of infantile cystinosis vs. control group consisting of patients who had 
been given only conservative and symptomatic treatment (CaST). MethOds: 
Markov model was developed in TreeAge Pro 2009. The model evaluated the costs 
and health outcomes of cysteamine treatment at a dose of 1.30 g/m2/day com-
pared with the use of CaST. The model distinguished two populations, depending 
on the time of initiation of the treatment (before the age of two – P1 and after 
the age of two – P2, which implies worse prognosis for the time of occurrence of 
end stage renal disease (ESRD)). The CEA was conducted from both a common 
payer perspective (a patient and a public payer) and a public payer perspective. 
The time horizon of the analysis covered the period from the age of one or four 
(depending on the start of cysteamine therapy) to fifty (currently, the oldest liv-
ing patients with cystinosis reach the fifth decade of life). The main measures 
of the outcomes in the CEA were life-years gained (LYG) and life-years gained to 
the onset of ESRD. Results: From the common payer perspective the cost per 
LYG was PLN 95,337 and PLN 192,272, respectively for the population P1 and P2. 
Cost of LYG to the onset of ESRD was PLN 33,317 and PLN 64,163, respectively for 
populations P1 and P2. The results obtained from the public payer perspective 
did not differ significantly from the results obtained from the common payer 
perspective. cOnclusiOns: Cysteamine treatment of patients with cystinosis vs. 
therapy involving only CaST is more expensive, however produces better health 
